Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -21.29 Million USD | 44.23% |
| 2022 | -38.18 Million USD | -48.83% |
| 2021 | -25.65 Million USD | -33.59% |
| 2020 | -19.2 Million USD | -412.04% |
| 2019 | -3.75 Million USD | 1.71% |
| 2018 | -3.81 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.14 Million USD | -31.06% |
| 2024 Q2 | -6.91 Million USD | -12.41% |
| 2023 Q3 | -4.19 Million USD | 38.01% |
| 2023 Q4 | -4.69 Million USD | -11.87% |
| 2023 FY | -21.29 Million USD | 44.23% |
| 2023 Q1 | -6.26 Million USD | 11.17% |
| 2023 Q2 | -6.76 Million USD | -7.93% |
| 2022 Q3 | -11.94 Million USD | -41.59% |
| 2022 Q2 | -8.43 Million USD | -14.48% |
| 2022 FY | -38.18 Million USD | -48.83% |
| 2022 Q1 | -7.37 Million USD | 30.7% |
| 2022 Q4 | -7.05 Million USD | 40.95% |
| 2021 Q2 | -4.97 Million USD | -29.05% |
| 2021 FY | -25.65 Million USD | -33.59% |
| 2021 Q3 | -6.12 Million USD | -23.13% |
| 2021 Q4 | -10.63 Million USD | -73.64% |
| 2021 Q1 | -3.85 Million USD | -8.12% |
| 2020 Q2 | -11.36 Million USD | -513.53% |
| 2020 Q4 | -3.56 Million USD | -47.57% |
| 2020 Q3 | -2.41 Million USD | 78.75% |
| 2020 FY | -19.2 Million USD | -412.04% |
| 2020 Q1 | -1.85 Million USD | 14.61% |
| 2019 Q1 | -390.9 Thousand USD | 0.0% |
| 2019 FY | -3.75 Million USD | 1.71% |
| 2019 Q4 | -2.16 Million USD | -144.64% |
| 2019 Q3 | -886.9 Thousand USD | -216.3% |
| 2019 Q2 | -280.4 Thousand USD | 28.27% |
| 2018 FY | -3.81 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -2696.617% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -146.687% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 30.749% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 82.843% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -32.442% |
| Better Therapeutics, Inc. | -39.76 Million USD | 46.444% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -12.87% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -15.867% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 40.538% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 40.957% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 81.407% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -847.132% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 71.515% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 63.959% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -255.595% |
| Molecular Templates, Inc. | -8.12 Million USD | -162.112% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -40.303% |
| NexImmune, Inc. | -32.34 Million USD | 34.165% |
| Orgenesis Inc. | -55.36 Million USD | 61.536% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 15.711% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -27194.051% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -16.426% |
| Scopus BioPharma Inc. | -11.6 Million USD | -83.414% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 96.283% |
| Statera Biopharma, Inc. | -174.4 Million USD | 87.791% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -493.478% |
| Trevena, Inc. | -40.28 Million USD | 47.147% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -37301.201% |
| Vaccinex, Inc. | -20.25 Million USD | -5.15% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -1701.352% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 58.294% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -173.801% |